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Olfactory bulb neuroproteomics 
reveals a chronological 
perturbation of survival routes 
and a disruption of prohibitin 
complex during Alzheimer’s disease 
progression
Mercedes Lachén-Montes1, Andrea González-Morales1, María Victoria Zelaya1,2,3,  
Estela Pérez-Valderrama4, Karina Ausín4, Isidro Ferrer5, Joaquín Fernández-Irigoyen1,2,4 & 
Enrique Santamaría1,2,4
Olfactory dysfunction is among the earliest features of Alzheimer’s disease (AD). Although 
neuropathological abnormalities have been detected in the olfactory bulb (OB), little is known about 
its dynamic biology. Here, OB- proteome analysis showed a stage-dependent synaptic proteostasis 
impairment during AD evolution. In addition to progressive modulation of tau and amyloid precursor 
protein (APP) interactomes, network-driven proteomics revealed an early disruption of upstream 
and downstream p38 MAPK pathway and a subsequent impairment of Phosphoinositide-dependent 
protein kinase 1 (PDK1)/Protein kinase C (PKC) signaling axis in the OB from AD subjects. Moreover, 
a mitochondrial imbalance was evidenced by a depletion of Prohibitin-2 (Phb2) levels and a 
specific decrease in the phosphorylated isoforms of Phb1 in intermediate and advanced AD stages. 
Interestingly, olfactory Phb subunits were also deregulated across different types of dementia. Phb2 
showed a specific up-regulation in mixed dementia, while Phb1 isoforms were down-regulated in 
frontotemporal lobar degeneration (FTLD). However, no differences were observed in the olfactory 
expression of Phb subunits in progressive supranuclear palsy (PSP). To sum up, our data reflect, in 
part, the missing links in the biochemical understanding of olfactory dysfunction in AD, unveiling Phb 
complex as a differential driver of neurodegeneration at olfactory level.
Alzheimer’s disease (AD) is the most common form of senile dementia1. In general, two subgroups are rec-
ognized, a familial early-onset form, and a sporadic late-onset form, albeit 95% of the patients develop spo-
radic AD2. Together with typical symptoms such as memory loss and behavioral disorders, AD patients present 
olfactory dysfunction in 90% of the cases3. Interestingly, this deficit occurs at early stages of the disease and it 
is considered a premotor sign of neurodegeneration3, 4. The olfactory bulb (OB) is the first central structure of 
the olfactory pathway in the brain5. Multiple reports have evidenced neuropathological changes, and molecular 
alterations in the OB derived from rodent AD models, and human AD brains6, 7. Interestingly, the accumulation 
of beta-amyloid (Aβ) and phospho-Tau protein in the anterior olfactory nucleus and OB correlates with the 
1Clinical Neuroproteomics Group, Navarrabiomed, Departamento de Salud, Universidad Pública de Navarra, 
Pamplona, Spain. 2IDISNA, Navarra Institute for Health Research, Pamplona, Spain. 3Pathological Anatomy 
Department, Navarra Hospital Complex, Pamplona, Spain. 4Proteored-ISCIII. Proteomics Unit, Navarrabiomed, 
Departamento de Salud, Universidad Pública de Navarra, Pamplona, Spain. 5Institut de Neuropatologia, IDIBELL-
Hospital Universitari de Bellvitge, Universitat de Barcelona, L’Hospitalet de Llobregat, CIBERNED (Centro de 
Investigación Biomédica en Red de Enfermedades Neurodegenerativas), Barcelona, Spain. Joaquín Fernández-
Irigoyen and Enrique Santamaría jointly supervised this work. Correspondence and requests for materials should be 
addressed to E.S. (email: esantamma@navarra.es)
Received: 22 November 2016
Accepted: 26 July 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENtIFIC REPORtS | 7: 9115  | DOI:10.1038/s41598-017-09481-x
progression of olfactory deficits and the severity of the disease in other brain regions3, suggesting the potential 
utility of olfactory tissue in the early diagnosis of AD.
Taking into account the cellular complexity and protein heterogeneity present in the OB8, 9, proteome-wide 
analysis based on high-resolution MS10 has become an attractive technology to characterize and quantify the OB 
proteome in different biological contexts11. Although this unbiased technology has greatly enhanced the ability 
to characterize novel pathways particularly in brain areas associated with AD12, 13, few studies have examined 
the proteome profiling of the early-affected OB region with the aim to investigate incipient neurodegenerative 
changes in AD phenotypes. Mass-spectrometric exploration of the OB derived from AD models has revealed a 
clear proteostasis impairment in this olfactory region. In the APP/PS1 (Amyloid precursor protein/Preselinin 1) 
mouse model of AD, an early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid 
deposition in the OB7. Moreover, these early events are subsequently accompanied by multiple proteomic, phos-
phoproteomic, and glycoproteomic changes in the OB, leading to a disruption in signaling pathways related to 
synaptic plasticity and cytoskeletal dynamics during the progression of AD-associated amyloid pathology in APP/
PS1 mice14. However, the AD progression in APP/PS1 mice is reminiscent of, but not identical to human sporadic 
AD15. We consider that deciphering the progressive proteome-wide alterations that occurs in a stage-dependent 
manner in the human OB, might complement the integrated view of the biochemical pathways involved in the 
olfactory pathophysiology of AD. In this study, we used a discovery platform combining neuropathological diag-
nosis, label-free quantitative proteomics, physical and functional interaction data, and biochemical approaches 
in order to understand the means by which the molecular pathways harboured in the OB are chronologically reg-
ulated during AD progression. We have revealed an olfactory proteostasis impairment across neuropathological 
grading detecting: i) differential expression of 278 proteins between controls and AD phenotypes, ii) a progressive 
modulation of APP, and Tau interactome networks across AD stages, iii) alteration in MKK3-6/p38 MAPK, and 
PDK1/PKC signaling pathways, and iv) potential mitochondrial impairment due to the imbalance of Prohibitin 
(Phb) complex. Interestingly, a cross-disease study also pointed out that Phb subunits are differentially modulated 
in the OB across AD-related co-pathologies, providing mechanistic clues to the intriguing divergence of AD 
pathology across different types of dementias.
Results
Proteostasis impairment in the OB during AD progression. To determine the OB site-specific pro-
teomic signature during AD progression, a label-free MS-based approach was performed on OB tissue derived 
from AD subjects with different grading and controls with no known neurological history (Table 1). Among 
1311 quantified proteins across all experimental groups, 278 proteins tend to be differentially expressed between 
controls and AD phenotypes (Fig. 1a, Supplementary Table 1 and Supplementary Fig. 1). Our analysis revealed 
Cases age sex
Duration Brain PMI
Pathological 
diagnosis IHQ: Aβ in OB IHQ: TAU in OB
(years) weight (g) (hours) (NIA-AA) criteria MP DP Tangles neurites
Advanced AD
BCN349 70 M 4 1104 2,5 AD (A3B3C3) ++ +++ ++ +++
BCN367 89 M 13 1015 3 AD (A2B3C3) + +++ +++ +++
BCN369 86 M 8 973 2,5 AD (A3B3C3) + − + ++
BCN376 93 M 3 1050 2,4 AD (A3B3C3) + +++ +++ +++
intermediate AD
BCN0104 85 M 12 1115 3,3 AD (A2B2C2) − + +++ +++
BCN0136 97 F 9 900 n.d AD (A2B2C2) n.d n.d n.d n.d
BCN381 77 M 17 1103 1,5 AD (A2B2C1) − − ++ ++
BCN222 86 F 9 1000 3 AD (A2B2C2) − + ++ ++
Initial AD
BCN342 88 M 1 1400 3,45 AD (A2B1C2) ++ + ++ ++
BCN336 85 F 8 1130 2 AD (A2B1C1) − − + +
BCN358 80 M 5 1090 3 AD (A2B1C1) ++ ++ ++ +++
A12/0046 75 F n.d 1125 6 AD (A1B1C1) − − + +
A12/0067 72 F n.d 810 4 AD (A1B1C1) − − + +
Control
BCN362 72 M 1407 9 Thal 1 Cerad 1 no tau deposit − − − +
BCN283 99 M 992 3 No protein deposit+v.d − − − +
BCN387 81 F 1176 3,3 PART (Braak I)+v.d − − − +
Table 1. Subjects included in the proteomic study. The neuropathological assessment was performed according 
to Thal phases, CERAD score, NIA-AA guidelines and PART criteria. Aβ immunopositivity was scored on a 
4-tiered scale as: (−) negative, (+) 1–2 isolated Aβ depositions, (++) 3–4 Aβ depositions, and (+++) >4Aβ 
depositions. Graduation of phospho-TAU deposit: (−) negative +: low; ++: intermediate; +++high. PMI: 
post-mortem interval; n.d: not determined; MP: Mature plaques; DP: Diffuse plaques; v.d: vascular disease.
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that 110 olfactory proteins are differentially expressed in early AD stages, increasing the proteome alterations 
as the disease progresses (125, and 158 differential proteins in intermediate and advanced stages respectively) 
(Fig. 1b). The distribution between up-regulated and down-regulated proteins was very similar across AD grad-
ing (Fig. 1b). Interestingly, 24 proteins overlapped between all stages (Fig. 1c), suggesting a potential role during 
AD evolution (Table 2). This set of proteins mainly clustered in specific biological process like growth of neurites 
(CLASP2, CPNE1), long-term potentiation (PPP1R1B), protein degradation (USP7, PSMD12, PSMF1), neu-
ritogenesis (TNIK, S100B, STMN1), morphology of the nervous system (MUT, YES1), and synaptic plasticity 
(AP2S1, AP3D1, STXBP1). In order to evaluate the impact of AD in the OB at synaptic level, we have compared 
the OB differential expressed proteomes across AD staging with the information stored in three repositories con-
taining the largest number of synapse specific proteins (G2Cdb, Synaptome DB, and SynsysNet)16–18. The analysis 
revealed that 162 out of 278 differential proteins (58% of the differential protein set) tend to localize to synaptic 
terminal (63, 70, and 96 differentially expressed synaptic proteins in initial, intermediate, and advanced stages 
respectively) (Supplementary Fig. 2). This meta-analysis verified a progressive synaptic degeneration at the level 
of OB during AD progression.
Pathway-specific alterations during AD progression. In order to perform a proteome mapping anal-
ysis of the stage-dependent protein profiles across specific-neuronal processes, we used the IPA information of 
Figure 1. Differentially expressed proteins in the OB across AD-related phenotypes. (a) Volcano plots 
representing the fold-change of identified proteins with associated P values from the pair-wise quantitative 
comparisons of control vs initial AD stage (upper panel), control vs intermediate AD stage (middle panel), 
and control vs advanced AD stage (lower panel). In green, very significantly changed proteins (P < 0.01), 
in yellow, significantly changed proteins (P < 0.05) and in blue, unchanged proteins between the pair-wise 
comparisons. (b) Differential olfactory proteome distribution across AD stages. (c) Venn diagram of common 
and unique differential proteins between AD stages. The distribution of common and distinct proteins in initial, 
intermediate, and advanced stages is shown.
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experimental and predictive origin regarding central nervous system, in order to be confident about the potential 
affected signaling pathways. As shown in Fig. 2, neuronal processes such as neuritogenesis, growth and outgrowth 
of neurites, axonogenesis, and growth of axons are compromised across AD stages. Moreover, our results pointed 
out a stage-dependent deregulation of specific biological processes (Fig. 2 and Supplementary Table 2). Protein 
clusters involved in synaptic transmission, and morphology of neuroglia were specifically mapped in initial stages 
while protein groups involved in formation of OB and cell death of oligodendrocytes were exclusively detected in 
intermediate stages. Interestingly, a de-regulation in protein clusters related to branching of neurites and axons, 
astrocytosis, vesicle trafficking, and myelination appears throughout initial and advanced stages (Fig. 2).
Network-driven proteomics reveals an imbalance in the olfactory MKK3-6/p38 MAPK and 
PDK1/PKC signaling across AD grading. To enhance the analytical outcome of proteomic experi-
ments, we have performed proteome-scale interaction networks merging the olfactory proteins that tend to be 
de-regulated across stages of AD. To that end, a protein interactome map has been constructed for each stage 
using the IPA software (Fig. 3). In initial stages, a deregulation of cross-linkers between plasma membrane and 
actin-based cytoskeleton such as the protein complex ezrin-moesin-radixin (EZR-MSN-RDX) and regulators of 
the interaction between components of cell-cell junctions (L1CAM, CD9, CD81, CTTN, cadherin) suggested 
an imbalance in the cellular assembly and morphology at early AD stages (Fig. 3a). The functional clustering 
also suggested a central function of ERK1/2 mediating the structural stabilization at the level of OB (Fig. 3a). 
In accordance with these data, our group has previously demonstrated an early hyperactivation of ERK1/2 in 
the OB of AD subjects7. In intermediate stages, the proteome-scale interaction network reflected an impaired 
Table 2. Common differential expressed OB proteins across AD stages. The fold-change (FC) of differential 
proteins with associated p-values from the pair-wise comparisons of control vs each AD stage, together with 
Protein/gene names, protein code by Uniprot, and unique peptides used for quantitation are shown. The 
significant downward or upward trend is represented in green or red color respectively. Proteins that are 
functional interactors of APP and Tau proteins are also indicated.
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mitochondrial function and an imbalance in redox signaling, due to dysregulation of subunits of mitochon-
drial respiratory chain complexes I, and IV (COX5A, COX7A2, COX6B1, NDUFV2) and protein components 
involved in antioxidant defense mechanisms (HSPE1, GSTM1, TXN2) (Fig. 3b). In advanced stages, the func-
tional interactome network indicated an alteration in HNRNP complexes (FUS, HNRNPA1, HNRNPH1) 
and specific RNA binding proteins (EFTUD2, and MATR3), suggesting an impairment in RNA stability, and 
pre-mRNA splicing processes. Moreover, the alteration of COP9 signalosome complex subunit 1 (GPS1), and 
cullin-3 (CUL3) pointed out an alteration in the proteasomal degradation pathway in advanced stages of the dis-
ease (Fig. 3c). Both p38 MAPK and PKC appeared as principal nodes in protein interactome maps (Fig. 3b and c). 
Even though changes in their expression were not detected in our proteomic experiments, the alteration of some 
of their targets may be compatible with a dysregulation of their functionality during AD progression at the level 
of OB. Subsequent experiments were performed to monitor the activation state of p38 MAPK and PKC signaling 
pathways across AD stages. MKK3 and MKK6 are two closely related dual-specificity protein kinases that activate 
p38 MAPK19. Western-blot analysis revealed a decrease in the activation status of upstream MKK3 and MKK6 
in initial AD stages (Fig. 4a). This early down-regulation was accompanied by a fall in p38 MAPK levels and a 
paralleled decrease in ATF2 and HSP27 phosphorylation (Fig. 4b), well-known downstream substrates of p38 
MAPK20, 21. However, olfactory p38 MAPK activity tends to increase during AD progression, as demonstrated 
by the increment in the phosphorylation status of HSP27 and ATF2 in advanced stages (Fig. 4b). PDK1 activity 
depends on the autophosphorylation on Ser241 and activates PKC signal transduction by phosphorylation on the 
activation loop22, 23. Although, a significant up-regulation in total PDK1 and PKC levels was evidenced in early 
stages (Fig. 4c), PDK1 inactivation was accompanied by a decrease in the activation status of PKC isoforms in 
intermediate stages, as revealed by Western-blot using a specific antibody against phosphorylated PKC isoforms 
at a residue homologous to activated Thr514 of human PKCγ (Fig. 4c). Accompanying the PKC inactivation, 
Myristoylated alanine-rich C-kinase substrate (MARCKS), a substrate of PKC24 was also down-regulated in inter-
mediate stages (Supplementary Table 1). However, the accumulation of PKC isoforms maintained PKC active in 
advanced stages, despite the PDK1 inactivation observed in these stages (Fig. 4c). Altogether, an early disruption 
in upstream p38 MAPK pathway and a subsequent impairment of PDK1/PKC signaling axis occurs in the OB 
from AD subjects. However, the tangled regulatory mechanisms that govern the PKC signaling needs further 
exploration, to elucidate the specific role of each PKC isoform during the AD neurodegeneration that occurs in 
the OB.
Dysregulation of AD-related protein interactomes in the OB during the neurodegenerative 
process. We consider that the discovery of unexpected relationships between apparently unrelated proteins 
and AD-causing neuropathological substrates is a powerful strategy for the characterization of novel AD caus-
ative/susceptibility proteins with a central role during the neurodegenerative process that occurs in olfactory 
areas. We explored whether well-established AD-related proteins were indeed highly interconnected with the 
stage-dependent differential olfactory proteomes. As shown in Fig. 5, differential functional interactors for 
neuropathological substrates like APP and tau proteins were identified in the OB. With respect to OB controls, 
the APP interactome was composed by 12, 24, and 32 differential targets in initial, intermediate, and advanced 
AD stages respectively (Supplementary Fig. 3). In the case of tau protein, 9 differential targets were detected 
in early AD stages, whereas 18 and 19 targets constituted the differential Tau interactome in intermediate and 
advanced AD stages respectively (Fig. 5 and Supplementary Fig. 4). Interestingly, 5 differential targets were shared 
between APP and Tau interactomes across AD grading. These proteins correspond to succinyl-CoA ligase [ADP/
GDP-forming] subunit alpha (SUCLG1), Stathmin 1 (STMN1), translationally-controlled tumor protein (TPT1), 
Figure 2. Functional metrics of the differential OB proteome across AD staging. Specific-neuronal pathway 
analysis for the differential OB proteomic expression profile detected in each AD stage is shown.
www.nature.com/scientificreports/
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protein S100-B (S100B), and syntaxin-binding protein 1 (STXBP1) (Supplementary Figs 3 and 4). Our analysis 
also revealed other functional interactomes that are modulated during AD progression in which the central nodes 
correspond to cAMP responsive element binding protein 1 (CREB1) and estrogen receptor 1 (ESR1) (Fig. 5 and 
Supplementary Figs 5 and 6).
Validation of differential olfactory proteins across AD grading: Focus on Prohibitin com-
plex. Previous studies identified a down-regulation of olfactory XRCC5, and FABP5 in initial AD stages, 
together with the overexpression of CD166 antigen, V-type proton ATPase subunit H, and histone H4 in 
advanced AD stages6. Our results confirm these previous observations (Supplementary Table 1), partially validat-
ing the label free-based liquid chromatography tandem mass spectrometry (LC-MS/MS) approach. With the aim 
to complement and validate quantitative proteome measurements, subsequent experiments were performed to 
check the steady-state levels of a subset of differential proteins using downstream assays. We consider the selec-
tion of assessing Vimentin (Vim) and Prohibitin-2 (Phb2) proteins for validation. The absence of the intermediate 
filament protein Vim exacerbates the amyloid plaque load and the increase in dystrophic neurites in APP/PS1 
mouse model of AD25 and Phb2 deficiency leads to Tau hyperphosphorylation, and neurodegeneration in mice26. 
First, we performed immunohistochemical analysis to localize Vim and Phb subunits in the OB region during 
AD progression (Fig. 6). Vim tends to be expressed in the glomerular layer and preferentially distributed in the 
walls of the blood vessels (Fig. 6). Both Phb subunits were detected at dendritic connections in glomerular layer 
Figure 3. High-scoring protein interactome maps for differentially expressed proteins in the OB during AD 
progression. Visual representation of the relationships between differential expressed proteins and functional 
interactors in initial (a), intermediate (b), and advanced AD stages (c). Dysregulated proteins are highlighted 
in red (up-regulated) and green (down-regulated) for each stage. Continuous and discontinuous lines represent 
direct and indirect interactions respectively. The complete legend including main features, molecule shapes, and 
relationships is found in http://ingenuity.force.com/ipa/articles/Feature_Description/Legend.
www.nature.com/scientificreports/
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and across the neuropil, being highly expressed in the cytoplasm of mitral cells and neurons of the anterior olfac-
tory nucleus (AON) (Fig. 6). In order to evaluate the potential role of Vim and Phb subunits in the early-affected 
OB region in human AD phenotypes, protein expression levels were monitored by Western blotting across AD 
staging (Fig. 7). In accordance with proteomic data (Supplementary Table 1), immunoblotting analysis revealed 
a slight decrease in olfactory Vim protein levels in initial and advanced AD stages, and a down-regulation of 
Figure 4. Signaling pathways disrupted in the OB across AD grading. Levels and residue-specific 
phosphorylation of MKK3/6 (a), p38 MAPK, ATF2, and HSP27 (b), PDK1, and PKC (c) in the OB across AD 
phenotypes. Equal loading of the gels was assessed by Ponceau staining and hybridization with a GAPDH 
specific antibody. Right panels show histograms of band densities. Data are presented as mean ± SEM from 5 
independent OB samples per group. *P < 0.05 vs control group; **P < 0.01 vs control group. Representative 
Western blot gels (n = 3/experimental group) are shown. Full-length blots/gels are presented in Supplementary 
information.
www.nature.com/scientificreports/
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Phb2 protein levels in intermediate and advanced AD stages with respect to controls (Fig. 7a). Mitochondrial 
prohibitin complex (constituted by Phb1 and Phb2) modulates mitochondrial dynamics, participates in the mito-
chondrial respiratory complex assembly, and exerts beneficial effects on neurons by reducing free radical pro-
duction27, 28. Generally, repression of Phb2 is paralleled by a concomitant reduction of its assembly partner Phb1 
and vice versa26, 29. In agreement with our mass spectrometry (MS) data (Supplementary Table 1), Phb1 levels 
were unchanged across AD stages (Fig. 7a), pointing out that Phb subunits are not functionally interdependent 
in the OB during AD neurodegeneration. However, phosphorylated Phb1 isoforms at Thr258 and Y259 were 
down-expressed in intermediate and advanced AD stages (Fig. 7b), suggesting potential fluctuations in the Phb1 
interactome across AD stages.
OB protein expression of Prohibitin complex across Alzheimer-related co-pathologies. In 
contrast to the common separate investigation of neurological disorders, targeted cross-disease studies com-
paring shared molecular relationships may give new insights into possible olfactory perturbations common 
for all or some neurological backgrounds. To check the potential vulnerability of PHB complex across differ-
ent Alzheimer-related co-pathologies at the level of OB, we have evaluated the OB protein expression of Phb2, 
Phb1, Thr258-, and Y259-phosphorylated Phb1 isoforms by Western-blot across AD-related diseases (n = 28 OB 
samples) (Supplementary Table 3). We have included pathologies with common smell impairment like FTLD3, 
PSP where olfactory loss occurs to a lesser extent or is absent3, 30, and mixed dementia (Mix AD VD). Mixed 
dementia is a condition in which AD and vascular dementia occur at the same time, and both separate disor-
ders often display olfactory dysfunction31. As shown in Fig. 8a, steady-state and phosphorylated levels of Phb1 
remained unchanged in the OB from Mixed AD VD subjects respect to controls, while Phb2 protein expression 
is significantly increased. Moreover, a significant reduction in Phb1 expression (steady-state and phosphorylated 
levels) was detected in FTLD subjects, and no significant differences were observed with respect to Phb2 protein 
levels (Fig. 8b). On the other hand, both Phb subunits were statistically unchanged in PSP subjects, albeit 50% of 
PSP subjects presented a slight tendency to down-regulation in the case of Phb1 (Fig. 8c). Although equivalent 
olfactory deficits are observed between some AD-related co-pathologies, these data pointed out that the olfactory 
pattern of Phb subunits is proteinopathy-dependent, suggesting different mechanistic clues to the neurodegener-
ative process that occurs in the OB.
Discussion
During the last years, proteomics has emerged as a large-scale comprehensive approach to characterize and quan-
tify specific olfactory-related proteomes in ageing and neurodegeneration11. Due to the early involvement of the 
olfactory dysfunction in AD4, we consider that the application of tissue proteomics in the OB is an ideal approach 
that allows zooming-in where pathophysiological changes are taking place. In the current work, we have used 
a discovery platform combining neuropathological diagnosis, label-free quantitative proteomics, physical and 
functional interaction data, and biochemical approaches in order to determine the chronologic regulation of the 
OB proteome during AD progression. Our group has previously identified common and distinct olfactory tar-
gets across tauopathies and synucleopathies using a labeling proteomic approach6. The use of labeling strategies 
usually results in the identification of more proteins, but label-free methods allow us to analyze and compare 
more samples individually, indicating that both workflows are complementary32. It is important to note that due 
to technical reasons, only the most abundant OB proteins were explored. Consequently, alterations other than 
those reported in this study might also participate in the AD neurodegeneration at the level of the OB. However, 
according to our integrative meta-analysis (Supplementary Table 4), most of the differential OB proteins reported 
in this study has not been previously reported in differential proteomic studies performed in human AD brains.
In agreement with previous studies performed in the APP/PS1 mouse model of AD14, our data revealed a 
stage-dependent synaptic proteostasis impairment in the OB during AD pathogenesis, where more than 50% 
of the differential proteome across AD phenotypes tends to localize to synaptic ending. Interestingly, 17% of 
the OB differential proteome (47 out of 278 proteins), is also deregulated in hippocampal tissue during AD pro-
gression12, suggesting a coordinated regulation of specific protein modules across AD-related brain structures 
Figure 5. Functional interactome distribution across AD stages. The number of predicted functional 
interactors for hub proteins with impact in neurobiology is represented.
www.nature.com/scientificreports/
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that might turn out detrimental or potentially protective mechanisms during the disease evolution. The synaptic 
plasticity imbalance was accompanied by specific proteomic fingerprints that are dynamically modulated in a 
stage-dependent manner throughout the OB. Interestingly, 24 early-affected proteins involved in protein degra-
dation, growth of neurites, long-term potentiation, and neuritogenesis were deregulated across all stages, high-
lighting their potential importance for targeting AD at an early stage. Assuming that causative and susceptibility 
proteins tend to be highly interconnected in AD33, we have employed network-driven proteomics to yield novel 
insights into the signaling pathways that govern the evolution of AD at olfactory level. Our data point out that 
functional protein interactomes and specific pathways are dynamically modulated across AD staging in the OB, 
emphasizing the potential impact of stage-dependent analysis using high-throughput proteome screenings12. It 
has been proposed that the aberrant regulation of a subset of kinases may represent the triggering events leading 
to the spread of an aberrant signaling in AD34. In this context, the dysregulation of kinases regulating neuronal 
plasticity, learning, and memory have been proposed as the starting signal, which promotes neurotoxic out-
comes34, 35. Analyzing the upstream signaling interactions of the differentially expressed proteomes in the OB, we 
determined upstream regulators (ERK1/2, p38 MAPK, and PKC) that were highly interconnected with down-
stream regulated proteins. Despite ERK1/2 is a well-defined pro-survival factor, neuronal ERK has been reported 
to be involved in the induction of cell death, APP processing, and Tau phosphorylation36–38. Our data point out 
that olfactory ERK1/2 hyperactivation7 may be involved in the improper cytoskeletal coupling that occurs in 
olfactory neurons at early stages, probably driving the synaptic impairment39. p38 MAPK is a multifunctional 
kinase in AD pathophysiology40. It has been shown that p38 MAPK is activated by Aβ in cultured neurons41, 
mediates the inflammatory activation initiated by Aβ42, and phosphorylates Tau protein43, 44. In this regard, pre-
vious studies have demonstrated that p38 MAPK signaling cascade is overactivated in hippocampal and cortical 
regions at early stages of AD pathology45–47, being considered as a potential target to treat AD neurodegenera-
tion40. In contrast, we detected a specific upstream and downstream disruption in p38 MAPK pathway in early 
stages at the level of the OB, recovering normal levels in intermediate and advanced stages. This early deregula-
tion was further validated by paralleled decrease in ATF2 and HSP27 phosphorylation, well-known downstream 
substrates of p38 MAPK20, 21. In spite of detrimental effects of p38 MAPK activation during AD pathogenesis40, 
recent studies have dissected the role of specific p38 MAPK isoforms identifying different functions. It has been 
characterized that the inhibition of neuronal p38alpha, but not p38beta MAPK, provides neuroprotection in dif-
ferent neurotoxic environments48. Interestingly, a depletion of neuronal p38alpha MAPK attenuates Aβ pathology 
in AD mouse and cell models49. In line with these findings, the early down-regulation of p38 MAPK in olfactory 
neurons might be part of the neuroprotective mechanisms induced in initial stages against Aβ. In addition, a 
Figure 6. Immunohistochemical localization of OB Vim, Phb1 and Phb2 across AD grading. First 
line: Representative immunohistochemical staining pattern of Vim across AD grading. Positive 
staining in glomerular cell layer (GL) and wall of endothelial cells (ovals). Second line: Representative 
immunohistochemical staining pattern of Phb1 across AD grading. Positive staining in glomerular layer (GL), 
anterior olfactory nucleus (AON), and mitral cells (asterisks). Third line: Representative immunohistochemical 
staining pattern of Phb2 across AD grading. Positive staining in glomerular layer (GL), anterior olfactory 
nucleus (AON), and mitral cells (asterisks).
www.nature.com/scientificreports/
1 0SCIENtIFIC REPORtS | 7: 9115  | DOI:10.1038/s41598-017-09481-x
subsequent impairment of PDK1/PKC signaling axis occurs in the OB from AD subjects. An increment in PDK1 
activity has been reported in the brain from AD patients50, however, its inhibition or silencing points out a ben-
eficial effect in AD-like pathology. In vitro studies have demonstrated that inhibition of PDK1 blocks neuronal 
cell death induced by Aβ51. Interestingly, quenching PDK1 activity in three APP-transgenic mouse models of AD 
rescued TACE-mediated neuroprotective cleavage of APP, and decreased Aβ deposition, counteracting memory 
and cognitive deficits50. Thus, our data suggest that the significant reduction in PDK1 activation may be a signal 
to protect neuronal function in the OB. PDK1 is an upstream regulator of some PKC family members52, critically 
involved in memory acquisition and maintenance53. Deficits in neuronal PKC signal cascades are one of the ear-
liest abnormalities in AD brains54. Aβ can directly inhibit PKC isoforms, induces PKC degradation, and reduces 
PKC-mediated phosphorylation and membrane translocation55–57. In line with these findings, the PKC inacti-
vation observed in the OB, could contribute to the Aβ-related toxicity across initial-intermediate phases of AD. 
Although PKC activation has been proposed for the treatment of dementias58, the tangled regulatory mechanisms 
that govern the PKC signaling needs further exploration at olfactory level, in order to clarify the specific role of 
each PKC isoform during the neurodegenerative process53.
Our proteomic screening further suggested an impairment of mitochondrial function in the OB6, revealing 
dysregulation of 29 mitochondrial proteins across intermediate and advanced AD stages. This impairment is a 
common finding in human AD brains, and also in rodent, and cellular AD models59, where intracellular Aβ accu-
mulation leads to a decrease electron transfer efficiency, reduce ATP production, and increase ROS production60. 
Interestingly, cross-validation by immunoblotting analysis revealed a down-regulation of Phb2 protein levels in 
intermediate and advanced stages. Phb complex (constituted by Phb1 and Phb2) is located in the mitochondrial 
inner membrane acting as a membrane-bound chaperone involved in the correct folding and assembly of some 
of the components of the mitochondrial respiratory chain61. According to this hypothesis, a deficiency in Phb2 
Figure 7. Olfactory expression of Vim and Phb subunits across AD stages. (a) Protein levels of Vim, Phb2, 
and Phb1 were monitored by Western-blotting. Equal loading of the gels was assessed by Ponceau staining 
and hybridization with a GAPDH specific antibody. Representative Western blot gels (n = 3/experimental 
group) are shown (left). Right panels show histograms of band densities. Data are presented as mean ± SEM 
from 3 independent OB samples per group. *P < 0.05 vs control group; ***P < 0.001 vs control group. (b) OB 
phosphorylation profiling of PHb1 across AD staging. Representative Western blot gels (n = 2/experimental 
group) are shown (left). Right panel shows histograms of band densities. Data are presented as mean ± SEM 
from 3 independent OB samples per group. *P < 0.05 vs control group; **P < 0.01 vs control group. Full-length 
blots/gels are presented in Supplementary information.
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may impair the native and functional organization of respiratory proteins, compromising mitochondrial func-
tionality28. Interestingly, neuron-specific deletion of Phb2 induces an aberrant mitochondrial ultrastructure, and 
Tau hyperphosphorylation in mice, leading to behavioral impairments and cognitive deficiencies26. Therefore, 
Phb2 deficiency might suggest a direct link between mitochondrial defects and tau pathology in olfactory neu-
rons. We have observed a reversed Phb2 pattern between mixed dementia (Mix AD VD) respect to the protein 
profile observed in AD. Transcriptional and translational events may explain the difference observed in Phb2 
protein levels. A possible explanation is that the vascular damage may induce a decrease in the Phb2 degradation 
rate at mRNA and/or protein levels at the level of the OB in mix AD VD. However, we should consider that the 
activation/inhibition of the transcription factor machinery that regulates the transcription of PHB2 gene may 
also be compromised (as a consequence of the vascular damage), leading to an increase in Phb2 mRNA and 
protein levels. However, additional validation studies should be conducted employing large cohorts to verify the 
protein expression changes observed in our sample set. Repression of Phb2 is usually paralleled by a concomitant 
reduction of its assembly partner Phb1 and vice versa26. However, in agreement with previous studies performed 
in frontal cortex derived from AD subjects62, steady-state levels of OB Phb1 was unchanged across AD grading, 
demonstrating that Phb subunits are not functionally interdependent in the OB during AD neurodegeneration. 
In addition, Phb1 and Phb2 are present in different subcellular localizations, presenting clear and distinctive 
Figure 8. OB protein expression of Phb isoforms across AD-related proteinopathies. Olfactory expression 
of Phb2, Phb1, and Phb1 phosphorylated isoforms in Mix AD VD (a), FTLD (b), and PSP (c). Representative 
Western blot gels are shown for each Phb subunit. Histograms of band densities derived from 28 independent 
OB samples. Data are presented as mean ± SEM from: Controls (n = 4 cases), mixed dementia (mix AD VD) 
(n = 9 cases), FTLD (n = 6 cases), and PSP (n = 9 cases). *P < 0.05 vs control group; **P < 0.01 vs control 
group. Full-length blots/gels are presented in Supplementary Information.
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functions63. While some associations at the plasma membrane and in the mitochondria require both Phb1 and 
Phb2, both proteins function independently in the nucleus, influencing the activity of multiple transcription 
factors64. However, based on our immunohistochemical analysis, most of Phb2 staining is not detected in the 
nucleus of olfactory neurons, suggesting that Phb2 may not be directly involved in transcriptional events. On the 
other hand, Phb subunits are post-translationally modified by O-linked N-acetylglucosamine, palmitoylation, 
transamidation, nytrosylation, and phosphorylation65. A decreased in phosphorylated Phb1 isoforms at T258 
and Y259 was detected in the OB from AD subjects. Both residues are present in the C-terminal coiled-coil 
domain that is involved in protein-protein interactions, including the interaction between Phb1 and Phb2 as well 
as transcriptional regulation66. Although the kinase that phosphorylates the Y259 remains unknown, it is well 
documented that Akt phosphorylates Phb1 at T258 in non-neuronal contexts. Specifically, Akt may phosphoryl-
ate this residue in the cytoplasm, promoting Phb1 mitochondrial translocation67 or in the lipid raft domain of the 
plasma membrane to activate the Ras-MAPK and PI3K/Akt pathways68. However, previous work in our labora-
tory demonstrated that the activation state of Akt remains unchanged, and ERK is hyper-activated in the OB from 
AD subjects7, suggesting that OB Phb1 dephosphorylation may be due to a phosphatase action or the inactivation 
of a specific kinase different than Akt. Although our results serve as a foundation for new areas of investigation 
into the role of olfactory signaling in human AD-related co-pathologies, further work is necessary to clarify the 
regulatory mechanisms involved in post-translational modifications of Phb subunits, in order to understand the 
final effect of olfactory Phb complex on cell survival and apoptosis across proteinopathies.
Methods
Materials. The following reagents and materials were used: anti-GAPDH (Calbiochem), anti-MKK3, anti-
MKK6, anti-phospho MKK3 (Ser189)/MKK6 (Ser207), anti-p38 MAP kinase, anti-phospho p38 MAP kinase 
(Thr180/Tyr 182), anti-phospho HSP27 (Ser82), anti-phospho ATF2 (Thr71), anti-PDK1, anti-phospho PDK1 
(S241), anti-PKC-Pan, anti-phospho PKC-pan (T514), anti-Prohibitin 1 (Phb1), anti-Prohibitin 2 (Phb2), (Cell 
signaling). Anti-vimentin antibody was purchased from Santa Cruz biotechnology. Anti-phospho Phb1 (T258), 
and anti-phospho Phb1 (Y259) were purchased from Signalway Antibody. Electrophoresis reagents were pur-
chased from Biorad and trypsin from Promega.
Human samples. According to the Spanish Law 14/2007 of Biomedical Research, inform written consent 
forms of the Neurological Tissue Bank of Navarra Health Service, Brain Bank of IDIBELL, and Neurological 
Tissue Bank of IDIBAPS-Hospital Clinic (Barcelona, Spain) was obtained for research purposes from relatives 
of patients included in this study. The study was conducted in accordance with the Declaration of Helsinki and 
all assessments, post-mortem evaluations, and procedures were previously approved by the Clinical Ethics 
Committee of Navarra Health Service. For the proteomic phase, fourteen AD cases were distributed into different 
groups according to specific consensus diagnostic criteria69–71: initial, intermediate, and advanced AD stages 
(n = 4–5/group). Three cases from elderly subjects with no history or histological findings of any neurological dis-
ease were used as a control group. All human brains considered in the proteomic study had a post-mortem inter-
val (PMI) lower than 10 hours (Table 1). Brain processing and the neuropathological study for protein deposits 
aggregates Aβ and phospho-Tau were performed as previously described6. For the discovery phase, neuropatho-
logical assessment was performed according to standardized neuropathological scoring/grading systems, includ-
ing Thal phases of Beta-amyloid deposition, Braak staging of neurofibrillary lesions, Consortium to Established a 
Registry for Alzheimer’s Disease, National Institute on Aging-Alzheimer’s Association (NIA-AA) guidelines, and 
primary age-related tauopathy (PART) criteria69–73. For the validation phase, OB tissue from additional controls 
and AD subjects were included (n = 4–5/group) (Supplementary Table 3). This material was obtained from the 
Neurological Tissue Banks of IDIBELL and IDIBAPS-Hospital Clinic, Barcelona, Spain. For the specificity anal-
ysis, different NDs were considered: Progressive supranuclear palsy (PSP) (n = 9 cases; 4F/5M; median age: 74 
years), frontotemporal lobar degeneration (FTLD) (n = 6; 3F/3M; median age: 81 years), mixed dementia (mix 
AD VD) (n = 9 cases; 4F/5M; median age: 85 years), and controls (n = 4; 1F/3M; median age: 79 years). In these 
cases, neuropathological assessment was performed according to standardized neuropathological guidelines: 
Mackenzie criteria for FTLD pathology74, NINDS-AIREN criteria for vascular dementia75, and NINDS criteria 
for PSP76. 80% of the OB samples included in this phase had a PMI lower than 10 hours (Supplementary Table 3).
Sample preparation for proteomic analysis. OB specimens derived from control and AD cases were 
homogenized in lysis buffer containing 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 50 mM DTT. The homogenates 
were spinned down at 100.000 × g for 1 h at 15 °C. Prior to proteomic analysis, protein extracts were precipitated 
with methanol/choloroform, and pellets dissolved in 6M Urea, Tris 100mM pH 7.8. Protein quantitation was 
performed with the Bradford assay kit (Bio-Rad).
Label free LC-MS/MS. The protein extract for each sample was diluted in Laemmli sample buffer and 
loaded into a 0.75 mm thick polyacrylamide gel with a 4% stacking gel casted over a 12.5% resolving gel. The run 
was stopped as soon as the front entered 3 mm into the resolving gel so that the whole proteome became con-
centrated in the stacking/resolving gel interface. Bands were stained with Coomassie Brilliant Blue and excised 
from the gel. Protein enzymatic cleavage (10 ug) was carried out with trypsin (Promega; 1:20, w/w) at 37 °C for 
16 h as previously described77. Purification and concentration of peptides was performed using C18 Zip Tip 
Solid Phase Extraction (Millipore). Peptides mixtures were separated by reverse phase chromatography using an 
Eksigent nanoLC ultra 2D pump fitted with a 75 μm ID column (Eksigent 0.075 × 250). Samples were first loaded 
for desalting and concentration into a 0.5 cm length 100 μm ID precolumn packed with the same chemistry as 
the separating column. Mobile phases were 100% water 0.1% formic acid (FA) (buffer A) and 100% Acetonitrile 
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0.1% FA (buffer B). Column gradient was developed in a 240 min two step gradient from 5% B to 25% B in 210 
min and 25%B to 40% B in 30 min. Column was equilibrated in 95% B for 9 min and 5% B for 14 min. During 
all process, precolumn was in line with column and flow maintained all along the gradient at 300 nl/min. Eluting 
peptides from the column were analyzed using an Sciex 5600 Triple-TOF system. Information data acquisition 
was acquired upon a survey scan performed in a mass range from 350 m/z up to 1250 m/z in a scan time of 250 
ms. Top 35 peaks were selected for fragmentation. Minimum accumulation time for MS/MS was set to 100 ms 
giving a total cycle time of 3.8 s. Product ions were scanned in a mass range from 230 m/z up to 1500 m/z and 
excluded for further fragmentation during 15 s.
Peptide Identification and Quantification. MS/MS data acquisition was performed using Analyst 1.7.1 
(AB Sciex) and spectra files were processed through Protein Pilot Software (v.5.0-ABSciex) using Paragon™ 
algorithm (v.4.0.0.0) for database search78, Progroup™ for data grouping, and searched against the concate-
nated target-decoy UniProt proteome reference Human database (Proteome ID: UP000005640, 70902 proteins, 
December 2015). False discovery rate was performed using a non lineal fitting method79 and displayed results 
were those reporting a 1% Global false discovery rate or better. The peptide quantification was performed using 
the Progenesis LC−MS software (ver. 2.0.5556.29015, Nonlinear Dynamics). Using the accurate mass measure-
ments from full survey scans in the TOF detector and the observed retention times, runs were aligned to compen-
sate for between-run variations in our nanoLC separation system. To this end, all runs were aligned to a reference 
run automatically chosen by the software, and a master list of features considering m/z values and retention times 
was generated. The quality of these alignments was manually supervised with the help of quality scores provided 
by the software. The peptide identifications were exported from Protein Pilot software and imported in Progenesis 
LC− MS software where they were matched to the respective features. Output data files were managed using 
R scripts for subsequent statistical analyses and representation. Proteins identified by site (identification based 
only on a modification), reverse proteins (identified by decoy database) and potential contaminants were filtered 
out. Proteins quantified with at least two unique peptides, an ANOVA p-value lower than 0.05, and an absolute 
fold change of <0.77 (down-regulation) or >1.3 (up-regulation) in linear scale were considered to be signifi-
cantly differentially expressed. MS raw data and search results files have been deposited to the ProteomeXchange 
Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository80 with the dataset 
identifiers PXD005319.
Bioinformatics. The proteomic data were analyzed through the use of QIAGEN’s Ingenuity® Pathway 
Analysis (IPA) (QIAGEN Redwood City, www.qiagen.com/ingenuity), in order to detect and infer differentially 
activated/deactivated pathways as a result of AD phenotypes. This software comprises curated information from 
databases of experimental and predictive origin, enabling discovery of highly represented functions, pathways, 
and interactome networks.
Immunohistochemistry. For the immunohistochemical study, formalin fixed sections (3–5 mm-thick) 
were mounted on slides and deparaffinized. Tissue sections were labelled with the following primary antibodies: 
anti-vimentin (dilution 1/200), anti-Prohibitin-1 (Phb1) (dilution 1/120), and anti-Prohibitin-2 (Phb2) (dilution 
1/50). The reaction product was visualized using an automated slide immunostainer (Leica Bond Max) with Bond 
Polymer Refine Detection (Leica Biosystems Newcastle Ltd).
Immunoblotting analysis. Equal amounts of protein (10 μg) were resolved in 12.5% SDS-PAGE gels. OB 
proteins derived from human samples were electrophoretically transferred onto nitrocellulose membranes using 
a Trans-blot Turbo transfer system (up to 25V, 7min) (Bio-rad). Equal loading of the gels was assessed by Ponceau 
staining. Membranes were probed with primary antibodies at 1:1000 dilution in 5% nonfat milk or BSA. After 
incubation with the appropriate horseradish peroxidase-conjugated secondary antibody (1:5000), the immunore-
activity was visualized by enhanced chemiluminiscence (Perkin Elmer) and detected by a Chemidoc MP Imaging 
System (Bio-Rad). After densitometric analyses (Image Lab Software Version 5.2; Bio-Rad), optical density values 
were expressed as arbitrary units and normalized to GAPDH.
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